Corbus Pharmaceuticals Holdings, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Yuval Cohen
- Full Time Employees
- 36
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 500 River Ridge Drive Norwood MA United States of America 02062
- IPO Date
- Oct 27, 2014
- CIK
- 0001595097
- Website
- corbuspharma.com
- Similar Companies
- Business
- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and obesity by targeting well-understood biological pathways. The company's pipeline features three key investigational candidates: CRB-701, a next-generation antibody-drug conjugate targeting Nectin-4 expression on solid tumors to deliver a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody that blocks TGFβ activation in αvβ8-enriched solid tumors to enhance immune response; and CRB-913, a peripherally restricted CB1 receptor inverse agonist for obesity and related metabolic conditions. Founded in 2009 and headquartered in Norwood, Massachusetts, Corbus conducts clinical development primarily in the United States and Europe, with CRB-701 also sponsored by CSPC in China; it relies on third-party contract manufacturers and licensing partners for production. Recent developments include dosing the first patient in the CRB-601 Phase 1 trial in December 2024, expecting first patient in for CRB-913 in Q1 2025, expanding multiple cohorts for CRB-701, and raising $75 million in an underwritten public offering in November 2025 to fund pipeline advancement and general corporate purposes.
Company News
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge
Assenagon Asset Management S.A. Has $1.53 Million Holdings in Corbus Pharmaceuticals Holdings, Inc. $CRBP
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference